Dupilumab Cuts Lung Inflammation, Breaks Up Mucus Plugs in Asthma Patients
WASHINGTON — Dupilumab (Dupixent) reduced airway inflammation and increased lung capacity in patients with uncontrolled, moderate-to-severe asthma, while also reducing troublesome mucus plugs, a multinational postmarketing study showed. In the randomized study, treatment with dupilumab led to significant reductions in airway inflammation at 24 weeks, with 57% achieving a fractional exhaled nitric oxide (FeNO) level […]
First Treatment Approved for Eosinophilic Esophagitis
Dupilumab (Dupixent) became the first drug approved to treat eosinophilic esophagitis in adults and pediatric patients ages 12 and older weighing at least 40 kg (~88 lb), the FDA announced. Eosinophilic esophagitis is a chronic, progressive disease in which the esophagus becomes inflamed due to a buildup of eosinophils, creating difficulty swallowing and eating. Dupilumab […]
Dupilumab May Help in Tough-to-Treat Chronic Spontaneous Urticaria
PHOENIX — Patients who received add-on dupilumab (Dupixent) treatment for chronic spontaneous urticaria (CSU) had reduced symptoms and experienced less itchiness, a phase III trial found. In the 6-month study, participants (adults, adolescents, and children) treated with dupilumab on top of their usual H1-antihistamine (H1-AH) experienced a 4.2-point greater mean reduction in their Itch Severity […]